Business Daily.
.
A+ R A-

Arrowhead Nominates ARC-HIF2 As First RNAi Therapeutic Candidate Using Extrahepatic DPC™ Delivery System

E-mail Print PDF
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research has nominated ARC-HIF2 as its first extrahepatic RNAi-therapeutic candidate to treat renal cell carcinoma

imageimage

Read more

Grow Your Business with Times Media
Business Daily Media